Clinical-Stage Companies / NoNO

NoNO

Pre-Approval PRO BETA

🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 10/2/2024

Total Trials

Phase 3

Phase 2

Recruiting

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Stroke, Acute Acute Ischemic Stroke First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke Acute Cerebral Ischemia Subarachnoid Hemorrhage

Clinical Trials (7)

NCT04462536 Phase 3 COMPLETED

Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Started: 12/6/2020

NCT02315443 Phase 3 COMPLETED

Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

Started: 3/26/2015

NCT02930018 Phase 3 COMPLETED

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

Started: 3/1/2017

NCT06403267 Phase 2 RECRUITING

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

Started: 10/2/2024

NCT02056574 Phase 2 WITHDRAWN

Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms

Started: 11/1/2015

NCT00728182 Phase 2 COMPLETED

Evaluating Neuroprotection in Aneurysm Coiling Therapy

Started: 8/1/2008

NCT05636306 Phase 1 COMPLETED

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

Started: 11/22/2022

Drug Candidates

NoNO-42 Nerinetide Nerinetide (NA-1) Nerinetide (NA-1), 2.6 mg/kg NA-1

Activity Status: Slowing

Last Trial Started: 10/2/2024

Last Trial Ended: 10/5/2023

Trials (12 months): 0

Completed Trials: 5

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.